Document:

Exhibit 4.3
​
DESCRIPTION OF CAPITAL STOCK OF GLAUKOS CORPORATION
​
References to “we,” “us” and “our” in this section refer to Glaukos Corporation.
​
General
​
The following is a summary of the rights of our common stock and preferred stock, and of certain provisions of our restated certificate of incorporation (our “certificate of incorporation”), our amended and restated bylaws (our “bylaws”), and certain provisions of applicable law. The following description is only a summary and is qualified by reference to our certificate of incorporation and our bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission.
​
Authorized Capitalization
​
Our authorized capital stock consists of shares, all with a par value of $0.001 per share, of which:
​
·      150,000,000 shares are designated as common stock; and
·      5,000,000 shares are designated as preferred stock.
​
As of February 25, 2021, 45,814,180 shares of our common stock were issued and 45,786,180 shares of our common stock were outstanding, and no shares of our preferred stock were issued or outstanding.
​
Common Stock
​
Voting
​
The holders of our common stock are entitled to one vote per share on all matters to be voted on by our stockholders. Our certificate of incorporation prohibits cumulative voting in the election of directors. Our bylaws provide for a plurality voting standard for the election of directors. Our certificate of incorporation includes certain supermajority voting provisions relating to the removal of directors, certain amendments to our certificate of incorporation and certain amendments to our bylaws.
​
Dividends
​
Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.
​
Liquidation
​
In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.
​
Rights and Preferences
​
Holders of common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.
​
Fully Paid and Nonassessable
​
All of our outstanding shares of common stock are fully paid and nonassessable.
​
​

Preferred Stock
​
Our board of directors has the authority, without further action by our stockholders, to designate and issue up to 5,000,000 shares of preferred stock in one or more series. Our board of directors may also designate the rights, preferences and privileges of each such series of preferred stock, any or all of which may be greater than or senior to those of our common stock. Though the actual effect of any issuance of preferred stock on the rights of the holders of common stock will not be known until our board of directors determines the specific rights of the holders of preferred stock, the potential effects of such an issuance include:
​
·      diluting the voting power of the holders of common stock;
​
·      reducing the likelihood that holders of common stock will receive dividend payments;
​
·      reducing the likelihood that holders of common stock will receive payments in the event of our sale, liquidation, dissolution, or winding up; and
​
·      delaying, deterring or preventing a change-in-control or other corporate takeover.
​
Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws
​
Delaware Law
​
Certain provisions of Delaware law and our certificate of incorporation and bylaws contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed in part to encourage anyone seeking to acquire control of us to negotiate with our board of directors. We believe that the advantages gained by protecting our ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could improve their terms.
​
Certificate of Incorporation and Bylaws
​
Our certificate of incorporation and/or bylaws include provisions that:
​
·      authorize our board of directors to issue, without further action by our stockholders, up to 5,000,000 shares of undesignated preferred stock;
​
·      require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;
​
·      specify that special meetings of our stockholders can be called only by our chairperson of the board of directors, our chief executive officer, our president or our board of directors acting pursuant to a resolution adopted by a majority of our board of directors;
​
·      establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;
​
·      provide that directors may be removed only for cause by a supermajority vote of the stockholders;
​
·      provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;
​
​

·      establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms;
​
·      specify that no stockholder is permitted to cumulate votes at any election of our board of directors; and
​
·      require a supermajority vote of the stockholders and a majority of our board of directors to amend certain of the above-mentioned provisions and our bylaws.
​
Exclusive Forum
​
Under the provisions of our certificate of incorporation and our bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of us; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim arising pursuant to any provision of the Delaware General Corporation Law (the “DGCL”), or our certificate of incorporation or bylaws; or (iv) any action asserting a claim governed by the internal affairs doctrine (the “Delaware Exclusive Forum Provision”). In addition, under the provisions of our bylaws, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action under the Securities Act of 1933, as amended (the “Federal Forum Provision”).
​
The Delaware Exclusive Forum Provision is intended to apply to claims arising under Delaware state law and would not apply to claims brought pursuant to the Securities Exchange Act of 1934, as amended (“Exchange Act”), or Securities Act of 1933, as amended (“Securities Act”), or any other claim for which the federal courts have exclusive jurisdiction. In addition, the Federal Forum Provision is intended to apply to claims arising under the Securities Act and would not apply to claims brought pursuant to the Exchange Act.  The exclusive forum provisions in our certificate of incorporation and our bylaws will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder and, accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal courts.  Our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.
​
Delaware Anti-Takeover Statute
​
We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder, unless:
​
·      prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;
​
·      upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not for determining the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who are directors and also officers, and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
​
·      at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock that is not owned by the interested stockholder.
​
​

Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation’s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may discourage business combinations or other attempts that might result in the payment of a premium over the market price for the shares of common stock held by our stockholders.
​
The provisions of Delaware law and our certificate of incorporation and bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.
​
Transfer Agent and Registrar
​
The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC.
​
Listing
​
Our common stock is listed on the New York Stock Exchange under the symbol “GKOS.”EX-10.1

 Exhibit 10.1 

SECURITIES PURCHASE AGREEMENT 

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 26, 2021 by and among
Satsuma Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). 

RECITALS 
 A. The Company
and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions of Section 4(a)(2) of the 1933 Act (as defined below), and Rule 506 of Regulation D
(“Regulation D”) as promulgated by the SEC (as defined below) under the 1933 Act; 
 B. The Investors wish to purchase from
the Company, and the Company wishes to sell and issue to the Investors, upon the terms and subject to the conditions stated in this Agreement, an aggregate of 14,084,507 shares (the “Shares”) of the Company’s Common
Stock, par value $0.0001 per share (the “Common Stock”); and 
 C. Contemporaneously with the sale of the Shares, the
parties hereto will execute and deliver a Registration Rights Agreement, in the form attached hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide
certain registration rights in respect of the Shares under the 1933 Act and applicable state securities laws. 
 In consideration of the
mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. Definitions. For the purposes of this Agreement, the following terms shall have the meanings set forth below: 

“Affiliate” means, with respect to any Person, any other Person which directly or indirectly through one or more
intermediaries Controls, is controlled by, or is under common Control with such Person. 
 “Business Day” means a day,
other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business. 

“Closing” has the meaning set forth in Section 3.1. 

“Closing Date” has the meaning set forth in Section 3.1. 

“Common Stock” has the meaning set forth in the recitals to this Agreement. 

“Company Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated
under the 1933 Act, any Person listed in the first paragraph of Rule 506(d)(1). 
  

 “Company’s Knowledge” means the actual knowledge of the executive
officers (as defined in Rule 405 under the 1933 Act) of the Company. 
 “Control” (including the terms
“controlling,” “controlled by” or “under common control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the
ownership of voting securities, by contract or otherwise. 
 “Disqualification Event” has the meaning set forth in
Section 4.31. 
 “EDGAR system” has the meaning set forth in Section 4.9. 

“Effective Date” has the meaning set forth in Section 7.4(b). 

“Environmental Laws” has the meaning set forth in Section 4.15. 

“GAAP” has the meaning set forth in Section 4.17. 

“Intellectual Property” has the meaning set forth in Section 4.14. 

“Losses” has the meaning set forth in Section 8.2. 

“Material Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations,
financial condition or business of the Company taken as a whole, (ii) the legality or enforceability of any of the Transaction Documents or (iii) the ability of the Company to perform its obligations under the Transaction Documents, except
that for purposes of Section 6.1(i) of this Agreement, in no event shall a change in the market price of the Common Stock alone constitute a “Material Adverse Effect”. 

“Material Contract” means any contract, instrument or other agreement to which the Company is a party or by which it is bound
that has been filed or was required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K. 

“Nasdaq” means the Nasdaq Global Market. 

“Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint
stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

“Placement Agent” means SVB Leerink LLC. 

“Press Release” has the meaning set forth in Section 9.7. 

“Principal Trading Market” means the Trading Market on which the Common Stock is primarily listed on and quoted for trading,
which, as of the date of this Agreement and the Closing Date, shall be the Nasdaq Global Market. 
 “Registration Rights
Agreement” has the meaning set forth in the recitals to this Agreement. 

  
 2 

 “Regulation D” has the meaning set forth in the recitals to this Agreement.

 “Regulatory Authorities” has the meaning set forth in Section 4.28. 

“Required Investors” has the meaning set forth in the Registration Rights Agreement. 

“SEC” means the U.S. Securities and Exchange Commission. 

“SEC Filings” has the meaning set forth in Section 4.8. 

“Shares” has the meaning set forth in the recitals to this Agreement. 

“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be
deemed to include the location and/or reservation of borrowable shares of Common Stock). 
 “Trading Day” means (i) a
day on which the Common Stock is listed or quoted and traded on its Principal Trading Market (other than the OTC Bulletin Board), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board), a day on which
the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market,
a day on which the Common Stock is quoted in the over-the-counter market as reported in the “pink sheets” by OTC Markets Group Inc. (or any similar
organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) or (iii) hereof, then Trading Day shall mean a Business Day. 

“Trading Market” means whichever of the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the
Nasdaq Global Market, the Nasdaq Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question. 

“Transfer Agent” has the meaning set forth in Section 7.4(a). 

“Transaction Documents” means this Agreement and the Registration Rights Agreement. 

“1933 Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated
thereunder. 
 “1934 Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules
and regulations promulgated thereunder. 
 2. Purchase and Sale of the Shares. On the Closing Date, upon the terms and subject to the
conditions set forth herein, the Company will issue and sell, and each Investor will purchase, severally and not jointly, the number of Shares set forth opposite the name of such Investor under the heading “Number of Shares to be
Purchased” on Exhibit A attached hereto. The purchase price per Share shall be $5.68. 

  
 3 

 3. Closing. 

3.1. Upon the satisfaction of the conditions set forth in Section 6, the completion of the purchase and sale of the
Shares (the “Closing”) shall occur remotely via exchange of documents and signatures at a time (the “Closing Date”) to be agreed to by the Company and the Investors but (i) in no event earlier than the second
Business Day after the date hereof and (ii) in no event later than the fifth Trading Day after the date hereof, and of which the Investors will be notified in advance by the Placement Agent. 

3.2. On the Closing Date, each Investor shall deliver or cause to be delivered to the Company, via wire transfer of immediately available funds
pursuant to the wire instructions delivered to such Investor by the Company on or prior to the Closing Date, an amount equal to the purchase price to be paid by the Investor for the Shares to be acquired by it as set forth opposite the name of such
Investor under the heading “Aggregate Purchase Price of Shares” on Exhibit A attached hereto. 
 3.3. At or before the
Closing, the Company shall deliver or cause to be delivered to each Investor a number of Shares, registered in the name of the Investor (or its nominee in accordance with its delivery instructions), equal to the number of Shares set forth opposite
the name of such Investor under the heading “Number of Shares to be Purchased” on Exhibit A attached hereto. The Shares shall be delivered via a book-entry record through the Company’s transfer agent. Unless the Company and an
Investor otherwise mutually agree with respect to such Investor’s Shares, at Closing settlement shall occur on a “delivery versus payment” basis. 

4. Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors that, except (a) as
described in the Company’s SEC Filings (as defined below) and (b) as set forth on the disclosure schedule delivered herewith (which is arranged in numbered and lettered sections corresponding to the numbered and lettered sections contained
in this Section 4) (the “Disclosure Schedule”), each of which qualify these representations and warranties in their entirety: 

4.1. Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own or lease its properties and to enter into and perform its obligations under the
Transaction Documents. The Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or
leasing necessary unless the failure to so qualify has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

4.2. Authorization. The Company has the requisite corporate power and authority and has taken all requisite corporate action necessary
for, and no further action on the part of the Company, its officers, directors and stockholders is necessary for, (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization of the performance of all
obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Shares. The Transaction Documents have been duly executed and delivered by the Company and constitute
the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability,
relating to or affecting creditors’ rights generally and to general equitable principles. 

  
 4 

 4.3. Capitalization. The Company is authorized under its Certificate of Incorporation
to issue 300,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock, par value $0.0001 per share. The Company’s disclosure of its issued and outstanding capital stock in its most recent SEC Filing containing such disclosure was
accurate in all material respects as of the date indicated in such SEC Filing. All of the issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued and are fully paid and nonassessable; none of
such shares were issued in violation of any preemptive rights; and such shares were issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties. No Person is entitled to preemptive
or similar statutory or contractual rights with respect to the issuance by the Company of any securities of the Company, including, without limitation, the Shares. Except for stock options granted under Company stock-based compensation plans
described in the SEC Filings, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any character under which the Company is or may be obligated to issue any equity securities of any kind,
except as contemplated by this Agreement. There are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other similar agreements among the Company and any of the
securityholders of the Company relating to the securities of the Company held by them. Except as provided in the Registration Rights Agreement, and except as provided in that certain Amended and Restated Investors’ Rights Agreement, dated as of
April 23, 2019, by and among the Company and certain investors signatory thereto, no Person has the right to (i) require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection
with the registration of securities of the Company for its own account or for the account of any other Person, or (ii) prohibit the Company from filing a registration statement under the 1933 Act. 

The issuance and sale of the Shares hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other
Person (other than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security. 

The Company does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect giving any
Person the right to purchase any equity interest in the Company upon the occurrence of certain events. 
 4.4. Valid Issuance. The
Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those created
by the Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. 

  
 5 

 4.5. Consents. Subject to the accuracy of the representations and warranties of each
Investor set forth in Section 5 hereof, the execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Shares require no consent of, action by or in respect of, or filing with, any
Person, governmental body, agency, or official other than (a) filings that have been made pursuant to applicable state securities laws, (b) post-sale filings pursuant to applicable state and federal securities laws, (c) filings
pursuant to the rules and regulations of Nasdaq and (d) filing of the registration statement required to be filed by the Registration Rights Agreement, each of which the Company has filed or undertakes to file within the applicable time.
Subject to the accuracy of the representations and warranties of each Investor set forth in Section 5 hereof, the Company has taken all action necessary to exempt (i) the issuance and sale of the Shares and (ii) the other transactions
contemplated by the Transaction Documents from the provisions of any stockholder rights plan or other “poison pill” arrangement, any anti-takeover, business combination or control share law or statute binding on the Company or to which the
Company or any of its assets and properties is subject that is or could reasonably be expected to become applicable to the Investors as a result of the transactions contemplated hereby, including without limitation, the issuance of the Shares and
the ownership, disposition or voting of the Shares by the Investors or the exercise of any right granted to the Investors pursuant to this Agreement or the other Transaction Documents. 

4.6. Use of Proceeds. The net proceeds of the sale of the Shares hereunder shall be used by the Company for working capital and general
corporate purposes. 
 4.7. No Material Adverse Change. Since September 30, 2020, except as identified and described in the SEC
Filings filed at least one Trading Day prior to the date hereof, there has not been: 
 (i) any change in the consolidated assets,
liabilities, financial condition or operating results of the Company from that reflected in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the nine month period ended
September 30, 2020 except for changes in the ordinary course of business which have not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 

(ii) any declaration or payment by the Company of any dividend, or any authorization or payment by the Company of any distribution, on any of
the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company; 
 (iii) any material
damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the Company; 
 (iv) any waiver, not in the
ordinary course of business, by the Company of a material right or of a material debt owed to it; 
 (v) any satisfaction or discharge of
any lien, claim or encumbrance or payment of any obligation by the Company, except in the ordinary course of business and which is not material to the assets, properties, financial condition, operating results or business of the Company (as such
business is presently conducted); 

  
 6 

 (vi) any change or amendment to the Company’s Certificate of Incorporation or Bylaws,
or material change to any material contract or arrangement by which the Company is bound or to which any of its assets or properties is subject; 

(vii) any material labor difficulties or, to the Company’s Knowledge, labor union organizing activities with respect to employees of the
Company; 
 (viii) any material transaction entered into by the Company other than in the ordinary course of business; 

(ix) the loss of the services of any key employee, or material change in the composition or duties of the senior management of the Company; or

 (x) any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect. 

4.8. SEC Filings. The Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by the
Company under the 1933 Act and the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, since the Company’s initial public offering (or such shorter period as the Company was required by law or regulation to file such material)
(collectively, the “SEC Filings”). The SEC Filings do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances
under which they were made, not misleading. At the time of filing thereof, the SEC Filings complied in all material respects with the requirements of the 1933 Act or the 1934 Act, as applicable, and the rules and regulations of the SEC thereunder.

 4.9. No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by the Company
and the issuance and sale of the Shares in accordance with the provisions thereof will not, except (solely in the case of clauses (i)(b) and (ii)) for such violations, conflicts or defaults as would not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect, (i) conflict with or result in a breach or violation of (a) any of the terms and provisions of, or constitute a default under, the Company’s Certificate of Incorporation or the
Company’s Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors through the Electronic Data Gathering, Analysis, and Retrieval system (the “EDGAR system”)), or
(b) assuming the accuracy of the representations and warranties in Section 5, any applicable statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company, or
any of their assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon
any of the properties or assets of the Company or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract. This Section does not relate to matters
with respect to tax status, which are the subject of Section 4.10, employee relations and labor matters, which are the subject of Section 4.13, or environmental laws, which are the subject of Section 4.15. 

  
 7 

 4.10. Tax Matters. The Company has timely prepared and filed all material tax returns
required to have been filed by them with all appropriate governmental agencies and timely paid all material taxes shown thereon or otherwise owed by them. There are no material unpaid assessments against the Company nor, to the Company’s
Knowledge, any audits by any federal, state or local taxing authority. All material taxes that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper governmental entity or
third party when due. There are no tax liens pending or, to the Company’s Knowledge, threatened against the Company or any of its assets or property. With the exception of agreements or other arrangements that are not primarily
related to taxes entered into in the ordinary course of business, there are no outstanding tax sharing agreements or other such arrangements between the Company and any other corporation or entity. 

4.11. Title to Properties. The Company has good and marketable title to all real properties and all other properties and assets owned by
them, in each case free from liens, encumbrances and defects, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and the Company holds any leased real or personal property under
valid and enforceable leases with no exceptions, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 

4.12. Certificates, Authorities and Permits. The Company possesses adequate certificates, authorities or permits issued by appropriate
governmental agencies or bodies necessary to conduct the business now operated by it, except where failure to so possess would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. The Company has not
received any written, and to the Company’s Knowledge, oral, notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that would reasonably be expected to have a Material Adverse Effect,
individually or in the aggregate, on the Company. 
 4.13. Labor Matters. 

(a) The Company is not party to or bound by any collective bargaining agreements or other agreements with labor organizations. The Company has
not violated in any material respect any laws, regulations, orders or contract terms affecting the collective bargaining rights of employees or labor organizations, or any laws, regulations or orders affecting employment discrimination, equal
opportunity employment, or employees’ health, safety, welfare, wages and hours. 
 (b) No material labor dispute with the employees of
the Company, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the Company’s Knowledge, is threatened or imminent. 

4.14. Intellectual Property. The Company owns, possesses, licenses or has other rights to use, all patents, patent applications, trade
and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, know-how and other intellectual property (collectively, the
“Intellectual Property”) necessary for the conduct of the Company’s business in all material respects as now conducted or as proposed in the SEC Filings to be conducted; and (a) there are no rights of third parties to any
such Intellectual Property, 

  
 8 

 
including no liens, security interests or other encumbrances; (b) to the Company’s Knowledge, there is no material infringement by third parties of any such Intellectual Property;
(c) there is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s rights in or to any such Intellectual Property; (d) such Intellectual Property that is
described in the SEC Filings has not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part; (e) there is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by
others challenging the validity or scope of any such Intellectual Property that is owned or licensed by the Company, including interferences, oppositions, reexaminations or government proceedings; (f) there is no pending or, to the
Company’s Knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates, or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others; and (g) to
the Company’s Knowledge, each Company employee involved with the development of Intellectual Property has entered into an invention assignment agreement with the Company. 

4.15. Environmental Matters. The Company is not in violation of any statute, rule, regulation, decision or order of any governmental
agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances
(collectively, “Environmental Laws”), has not released any hazardous substances regulated by Environmental Law onto any real property that it owns or operates and has not received any written notice or claim it is liable for any off-site disposal or contamination pursuant to any Environmental Laws, which violation, release, notice, claim, or liability would reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect, and to the Company’s Knowledge, there is no pending or threatened investigation that would reasonably be expected to lead to such a claim. 

4.16. Legal Proceedings. There are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which
the Company is or may reasonably be expected to become a party or to which any property of the Company is or may reasonably be expected to become the subject that, individually or in the aggregate, would reasonably be expected to have a Material
Adverse Effect. 
 4.17. Financial Statements. The financial statements included in each SEC Filing comply in all material respects
with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and present fairly, in all material respects, the
consolidated financial position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods shown, subject in the case of unaudited financial statements to normal, immaterial year-end audit adjustments, and such consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles applied on a consistent basis during the periods
involved (“GAAP”) (except as may be disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP, and, in the case of quarterly financial statements,
except as permitted by Form 10-Q under the 1934 Act). Except as set forth in the financial statements of the Company included in the SEC Filings filed prior to the date hereof, the Company has not incurred any
liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such financial statements, none of which, individually or in the aggregate,
have had or would reasonably be expected to have a Material Adverse Effect. 

  
 9 

 4.18. Insurance Coverage. The Company maintains in full force and effect insurance
coverage that is customary for comparably situated companies for the business being conducted and properties owned or leased by the Company, and the Company reasonably believes such insurance coverage to be adequate against all liabilities, claims
and risks against which it is customary for comparably situated companies to insure. 
 4.19. Compliance with Nasdaq Continued Listing
Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the
Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq. 

4.20. Brokers and Finders. Other than the Placement Agent, no Person will have, as a result of the transactions contemplated by the
Transaction Documents, any valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company.
No Investor shall have any obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section 4.20 that may be due in connection with the
transactions contemplated by this Agreement or the Transaction Documents. 
 4.21. No Directed Selling Efforts or General
Solicitation. Neither the Company nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any of the Shares. 

4.22. No Integrated Offering. Neither the Company nor any Person acting on its behalf has, directly or indirectly, made any offers or
sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) and Regulation D for the exemption from registration for the
transactions contemplated hereby or would require registration of the Shares under the 1933 Act. 
 4.23. Private Placement. Assuming
the accuracy of the representations and warranties of the Investors set forth in Section 5, the offer and sale of the Shares to the Investors as contemplated hereby is exempt from the registration requirements of the 1933 Act. The issuance and
sale of the Shares does not contravene the rules and regulations of Nasdaq. 
 4.24. Transactions with Affiliates. None of the
executive officers or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company (other than as holders of stock options, warrants and/or restricted
stock, and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 

  
 10 

 4.25. Internal Controls. The Company has established and maintains disclosure
controls and procedures (as defined in Rules 13a-15 and 15d-15 under the 1934 Act), which are designed to ensure that material information relating to the Company, is
made known to the Company’s principal executive officer and its principal financial officer by others within those entities. Since the end of the Company’s most recent audited fiscal year, there have been no material weaknesses in the
Company’s internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or would reasonably be expected to materially affect,
the Company’s internal control over financial reporting. The Company is not aware of any change in its internal controls over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or would
reasonably be expected to materially affect, the Company’s internal control over financial reporting. 
 4.26. Disclosures.
Neither the Company nor any Person acting on its behalf has provided the Investors or their agents or counsel with any information that constitutes material nonpublic information concerning the Company, other than with respect to the transactions
contemplated hereby and such information that will be disclosed in the Press Release or the 8-K Filing (each as defined below). The Company understands and confirms that the Investors will rely on the
foregoing representations in effecting transactions in securities of the Company. 
 4.27. Required Filings. Except for the
transactions contemplated by this Agreement, including the acquisition of the Shares contemplated hereby, no event or circumstance has occurred or information exists with respect to the Company or its business, properties, operations or financial
condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the SEC Filings are being incorporated by
reference into an effective registration statement filed by the Company under the 1933 Act). 
 4.28. Investment Company. The Company
is not required to be registered as, and immediately following the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 

4.29. Tests and Preclinical and Clinical Trials. All clinical and pre-clinical trials conducted
by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described or referred to in the SEC Filings were and, if still pending, are being conducted, in all material respects, in compliance with the
experimental protocols established for such trials, with accepted medical and scientific standards, and all applicable statutes and all applicable rules and regulations of the U.S. Food and Drug Administration and comparable regulatory agencies
outside of the United States to which they are subject, including the European Medicines Agency (collectively, the “Regulatory Authorities”) and Good Clinical Practice and Good Laboratory Practice requirements. The descriptions of
the clinical and pre-clinical trials, including the results thereof, contained in the SEC Filing are accurate and complete in all material respects and fairly present the data derived from such trials in all
material respects; and the 

  
 11 

 
Company is not aware of any other clinical or pre-clinical trials, the results of which reasonably call into question the results described in the SEC
Filings. The Company has not received any notices or correspondence from the Regulatory Authorities or institutional review boards or comparable authorities requiring the termination, suspension, material modification or clinical hold of any
clinical or pre-clinical trials conducted by or on behalf of the Company, and to the Company’s Knowledge, there are no reasonable grounds for the same. 

4.30. Manipulation of Price. The Company has not taken, and, to the Company’s Knowledge, no Person acting on its behalf has
taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares. 

4.31. Anti-Bribery and Anti-Money Laundering Laws. The Company, and any of its respective officers, directors, supervisors, managers,
agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A) anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality,
including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December 17, 1997, including the U.S. Foreign
Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope or (B) anti-money laundering laws, including, but not limited to, applicable federal, state, international,
foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering
principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States representative to the group or
organization continues to concur, all as amended, and any Executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder. 

4.32. No Bad Actors. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the 1933 Act (a
“Disqualification Event”) is applicable to the Company or, to the Company’s Knowledge, any Company Covered Person, except (i) for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3) is applicable and
(ii) no such representation is made with respect to the Placement Agent, or any of their respective general partners, managing members, directors, executive officers or other officers. 

4.33. No Additional Agreements. The Company has no other agreements or understandings (including, without limitation, side letters) with
any Investor to purchase Shares on terms more favorable to such Investor than as set forth herein. 
 4.34. Shell Company Status. The
Company is not, and has never been, an issuer identified in Rule 144(i)(1). 

  
 12 

 4.35. Compliance. The Company is not (i) in default under or in violation of
(and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company under), nor has the Company received notice of a claim that it is in default under or that it is in violation
of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived) or (ii) in violation of any
judgment, decree or order of any court, arbitrator or governmental body, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect. 

5. Representations and Warranties of the Investors. Each of the Investors hereby severally, and not jointly, represents and warrants to
the Company that: 
 5.1. Organization and Existence. Such Investor is a duly incorporated or organized and validly existing
corporation, limited partnership, limited liability company or other legal entity, has all requisite corporate, partnership or limited liability company power and authority to enter into and consummate the transactions contemplated by the
Transaction Documents and to carry out its obligations hereunder and thereunder, and to invest in the Shares pursuant to this Agreement, and is in good standing under the laws of the jurisdiction of its incorporation or organization. 

5.2. Authorization. The execution, delivery and performance by such Investor of the Transaction Documents to which such Investor is a
party have been duly authorized and each has been duly executed and when delivered will constitute the valid and legally binding obligation of such Investor, enforceable against such Investor in accordance with their respective terms, subject to
bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally, and general principles of equity. 

5.3. Purchase Entirely for Own Account. The Shares to be received by such Investor hereunder will be acquired for such Investor’s
own account, not as nominee or agent, for the purpose of investment and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and such Investor has no present intention of selling, granting any participation
in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose of all or any part of such Shares in compliance with applicable federal and state
securities laws. The Shares are being purchased by such Investor in the ordinary course of its business. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Shares for any period of time. Such Investor
is not a broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered. 

5.4. Investment Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of its investment in the
Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby. 

5.5. Disclosure of Information. Such Investor has had an opportunity to receive, review and understand all information related to the
Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares, and has conducted and completed its own independent due diligence.
Such Investor acknowledges that copies of the SEC Filings are available on the 

  
 13 

 
EDGAR system. Based on the information such Investor has deemed appropriate, and without reliance upon the Placement Agent, it has independently (or together with its investment adviser) made its
own analysis and decision to enter into the Transaction Documents. Such Investor is relying exclusively on its own investment analysis and due diligence (and/or that of its investment adviser) (including professional advice it deems appropriate)
with respect to the execution, delivery and performance of the Transaction Documents, the Shares and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all
business, legal, regulatory, accounting, credit and tax matters. Such Investor has not relied on any information or advice furnished by or on behalf of the Placement Agent in connection with the transactions contemplated hereby. Neither such
inquiries nor any other due diligence investigation conducted by such Investor (or its investment adviser) shall modify, limit or otherwise affect such Investor’s right to rely on the Company’s representations and warranties contained in
this Agreement. 
 5.6. Restricted Securities. Such Investor understands that the Shares are characterized as “restricted
securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without
registration under the 1933 Act only in certain limited circumstances. 
 5.7. Legends. It is understood that, except as provided
below, certificates or book-entry records evidencing the Shares may bear the following or any similar legend: 
 (a) “The securities
represented hereby have not been registered with the Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not
be transferred unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended, (ii) such securities may be sold pursuant to Rule 144, (iii) the Company has received an opinion of
counsel reasonably satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933, as amended, or (iv) the securities are transferred without consideration to an affiliate of such holder or a
custodial nominee (which for the avoidance of doubt shall require neither consent nor the delivery of an opinion).” 
 (b) If required
by the authorities of any state in connection with the issuance of sale of the Shares, the legend required by such state authority. 
 5.8.
Accredited Investor. Such Investor is an “accredited investor” within the meaning of Rule 501(a) of Regulation D. To the extent requested by the Company, such Investor will execute and deliver to the Company a questionnaire (to the
extent delivered, such Investor represents and warrants is true, correct and complete in all material respects) certifying that it is an “accredited investor”, including that such Investor: (a) is a sophisticated institutional
investor with sufficient knowledge and experience in investing in private equity transactions to properly evaluate the risks and merits of its purchase of the Shares; and (b) has determined based on its own independent review and such
professional advice as it deems appropriate that its purchase of the Shares and participation in the transactions contemplated by the Transaction Documents (i) are fully consistent with its financial needs, objectives and condition,
(ii) comply and are fully consistent with all investment policies, guidelines and other restrictions applicable to such 

  
 14 

 
Investor, (iii) have been duly authorized and approved by all necessary action, (iv) do not and will not violate or constitute a default under such Investor’s charter, bylaws or
other constituent document or under any law, rule, regulation, agreement or other obligation by which such Investor is bound and (v) are a fit, proper and suitable investment for such Investor, notwithstanding the substantial risks inherent in
investing in or holding the Shares. 
 5.9. Placement Agent. Such Investor hereby acknowledges and agrees that (a) the Placement
Agent is acting solely as placement agent in connection with the execution, delivery and performance of the Transaction Documents and is not acting as an underwriter or in any other capacity and is not and shall not be construed as a fiduciary for
such Investor, the Company or any other person or entity in connection with the execution, delivery and performance of the Transaction Documents, (b) the Placement Agent has not made and will not make any representation or warranty, whether
express or implied, of any kind or character, and has not provided any advice or recommendation in connection with the execution, delivery and performance of the Transaction Documents, (c) the Placement Agent will not have any responsibility
with respect to (i) any representations, warranties or agreements made by any person or entity under or in connection with the execution, delivery and performance of the Transaction Documents, or the execution, legality, validity or
enforceability (with respect to any person) thereof, or (ii) the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company, and (d) the Placement Agent will not have any
liability or obligation (including without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such Investor, the Company or any other
person or entity), whether in contract, tort or otherwise, to such Investor, or to any person claiming through it, in respect of the execution, delivery and performance of the Transaction Documents. 

5.10. No General Solicitation. Such Investor did not learn of the investment in the Shares as a result of any general or public
solicitation or general advertising, or publicly disseminated advertisements or sales literature, including (a) any advertisement, article, notice or other communication published in any newspaper, magazine, website, or similar media, or
broadcast over television or radio, or (b) any seminar or meeting to which such Investor was invited by any of the foregoing means of communications. 

5.11. Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid
right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor. 

5.12. Short Sales and Confidentiality Prior to the Date Hereof. Other than consummating the transactions contemplated hereunder, such
Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period
commencing as of the time that such Investor was first contacted by the Company, the Placement Agent or any other Person regarding the transactions contemplated hereby and ending immediately prior to 8:30 a.m. (New York City time) on Business Day
following the date hereof. Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers or desks manage separate portions of such

  
 15 

 
Investor’s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager or desk that made the investment decision to
purchase the Shares covered by this Agreement (the “Investing Portfolio Manager”) and the portfolio managers or desks who have direct knowledge of the investment decisions made by the Investing Portfolio Manager. Other than to other
Persons party to this Agreement and other than to such Person’s outside attorney, accountant, auditor, investment advisor, or other Representatives (as defined in the confidentiality agreement between the Company and such Investor) only to the
extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law, such Investor has maintained
the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a
representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. 

5.13. No Government Recommendation or Approval. Such Investor understands that no United States federal or state agency, or similar
agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase of the Shares. 

5.14. No Intent to Effect a Change of Control. Such Investor has no present intent to effect a “change of control” of the
Company as such term is understood under the rules promulgated pursuant to Section 13(d) of the 1934 Act. 
 5.15. Residency.
Such Investor’s office in which its investment decision with respect to the Shares was made is located at the address immediately below such Investor’s name on its signature page hereto. 

5.16. No Conflicts. The execution, delivery and performance by such Investor of the Transaction Documents and the consummation by such
Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Investor or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time
or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Investor is a party, or (iii) result in a violation of any law,
rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Investor, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not,
individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Investor to perform its obligations hereunder. 

6. Conditions to Closing. 

6.1. Conditions to the Investors’ Obligations. The obligation of each Investor to purchase Shares at the Closing is subject to the
fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to itself only): 

  
 16 

 (a) The representations and warranties made by the Company in Section 4 hereof shall be
true and correct in all material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects as of the date hereof and as of the Closing Date, as
though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier
date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date. 

(b) The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the
purchase and sale of the Shares and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect. 

(c) The Company shall have executed and delivered the Registration Rights Agreement. 

(d) The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares. 

(e) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court
or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated
hereby or in the other Transaction Documents. 
 (f) The Company shall have delivered a Certificate, executed on behalf of the Company by its
Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a), (b), (d), (e) and (j) of this Section 6.1. 

(g) The Company shall have delivered a Certificate, executed on behalf of the Company by its Secretary, dated as of the Closing Date,
certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement, the other Transaction Documents and the issuance of the Shares, certifying the current versions of the Certificate
of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company. 

(h) The Investors shall have received an opinion from Latham & Watkins LLP, the Company’s counsel, dated as of the Closing Date,
in form and substance reasonably acceptable to the Investors and addressing such legal matters as the Investors may reasonably request. 

(i) There shall have been no Material Adverse Effect with respect to the Company since the date hereof. 

  
 17 

 (j) No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any
other governmental or regulatory body with respect to public trading in the Common Stock. 
 6.2. Conditions to Obligations of the
Company. The Company’s obligation to sell and issue the Shares at the Closing (as to an Investor) is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may
be waived by the Company: 
 (a) The representations and warranties made by such Investor in Section 5 hereof shall be true and correct
in all material respects as of the date hereof, and shall be true and correct as of the Closing Date with the same force and effect as if they had been made on and as of such date, except to the extent any such representation or warranty expressly
speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date. . The Investors shall have performed in all material respects all obligations and covenants
herein required to be performed by such Investor on or prior to the Closing Date. 
 (b) The Investor shall have executed and delivered the
Registration Rights Agreement and, to the extent requested by the Company, such Investor’s questionnaire. 
 (c) The Investor shall have
paid in full its purchase price to the Company. 
 6.3. Termination of Obligations to Effect Closing; Effects. 

(a) The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:

 (i) Upon the mutual written consent of the Company and Investors that agreed to purchase a majority of the Shares to be issued and sold
pursuant to this Agreement; 
 (ii) By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of
fulfillment, and shall not have been waived by the Company; 
 (iii) By an Investor (with respect to itself only) if any of the conditions
set forth in Section 6.1 shall have become incapable of fulfillment, and shall not have been waived by the Investor; or 
 (iv) By
either the Company or any Investor (with respect to itself only) if the Closing has not occurred on or prior to the fifth Trading Day following the date of this Agreement; 

provided, however, that, except in the case of clause (i) above, the party seeking to terminate its obligation to effect the Closing shall not then be in
breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its
obligation to effect the Closing. 

  
 18 

 (b) In the event of termination by the Company or any Investor of its obligations to effect
the Closing pursuant to this Section 6.3, written notice thereof shall be given to the other Investors by the Company and the other Investors shall have the right to terminate their obligations to effect the Closing upon written notice to the
Company and the other Investors. Nothing in this Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the
right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. 

7. Covenants and Agreements of the Company. 

7.1. No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would
conflict or interfere in any material respect with the Company’s obligations to the Investors under the Transaction Documents. 
 7.2.
Nasdaq Listing. The Company will use reasonable best efforts to continue the listing and trading of its Common Stock on Nasdaq or other Trading Market and, in accordance therewith, will use reasonable best efforts to comply in all material
respects with the Company’s reporting, filing and other obligations under the bylaws or rules of such market or exchange, as applicable. 

7.3. Termination of Covenants. The provisions of Sections 7.1 and 7.2 shall terminate and be of no further force and effect on the
date on which the Company’s obligations under the Registration Rights Agreement to register or maintain the effectiveness of any registration covering the Registrable Securities (as such term is defined in the Registration Rights Agreement)
shall terminate. 
 7.4. Removal of Legends. 

(a) In connection with any sale, assignment, transfer or other disposition of the Shares by an Investor pursuant to Rule 144 or pursuant
to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor, the Company shall request the transfer agent
for the Common Stock (the “Transfer Agent”) to remove any restrictive legends related to the book entry account holding such Shares and make a new, unlegended entry for such book entry shares sold or disposed of without restrictive
legends within two (2) Trading Days of any such request therefor from such Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably acceptable to the Company in
connection therewith. 
 (b) Subject to receipt from the Investor by the Company and the Transfer Agent of customary representations and
other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares (i) are subject to an effective registration statement wherein the Investor is named as a
selling shareholder, (ii) have been sold or transferred pursuant to an effective registration statement, (iii) have been sold pursuant to Rule 144, or (iv) are eligible for resale under Rule 144(b)(1) or any successor provision
(such earliest date, the “Effective Date”), the Company shall 

  
 19 

 
promptly, in accordance with the provisions of this Section 7.4(b) and, in any event within two (2) Trading Days of any request therefor from an Investor accompanied by such customary
and reasonably acceptable documentation referred to above (including, in the case of an delegending request pursuant to clause (i) of this sentence, an acknowledgement letter as to the Investor’s continued obligations under the 1933 Act),
(A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Shares, (B) cause its counsel to deliver to the Transfer Agent one or more opinions to the effect
that the removal of such legends in such circumstances may be effected under the 1933 Act if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement and (C) to the extent requested
by an Investor cause its transfer agent to issue such Shares without such legends to the holders thereof by electronic delivery at the applicable balance account at the Depository Trust Company upon surrender of any stock certificates evidencing
such Shares. The Company agrees that following the Effective Date or at such time as such legend is no longer required under this Section 7.4, it will, within two (2) Trading Days of the delivery by an Investor to the Company or the
Transfer Agent of a certificate representing shares issued with a restrictive legend and receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable to the Company and
the Transfer Agent in connection therewith, deliver or cause to be delivered to such Investor a certificate representing such Shares (or uncertificated interest therein) that is free from all restrictive and other legends. Shares subject to legend
removal hereunder may be transmitted by the Transfer Agent to the Investor by crediting the account of the Investor’s prime broker with the DTC System as directed by such Investor. The Company shall be responsible for the fees of its Transfer
Agent and all DTC fees associated with such issuance. 
 (c) Each Investor, severally and not jointly with the other Investors, agrees with
the Company (i) that such Investor will sell any Shares only pursuant to either the registration requirements of the 1933 Act, including any applicable prospectus delivery requirements, or an exemption therefrom, (ii) that if Shares are
sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein and (iii) that if, after the effective date of the registration statement covering the resale of the Shares, such
registration statement ceases to be effective and the Company has provided notice to such Investor to that effect, such Investor will sell Shares only in compliance with an exemption from the registration requirements of the 1933 Act. 

7.5. Fees. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or
broker’s commissions (other than for Persons engaged by any Investor) relating to or arising out of the transactions contemplated hereby, including, without limitation, any fees or commissions payable to the Placement Agent. 

7.6. Short Sales and Confidentiality After the Date Hereof. Each Investor covenants that neither it nor any Affiliates acting on its
behalf or pursuant to any understanding with it will trade in the securities of the Company and will not execute any Short Sales during the period from the date hereof until the earlier of such time as (i) both (a) the transactions contemplated
by this Agreement are first publicly announced and (b) all material information set forth in the Disclosure Schedule, if any, have been publicly disclosed by the Company (which, for the avoidance of doubt, shall occur simultaneously) or
(ii) this Agreement is terminated in full. Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment 

  
 20 

 
vehicle whereby separate portfolio managers or desks manage separate portions of such Investor’s assets, the representation set forth above shall only apply with respect to the portion of
assets managed by the portfolio manager or desk that made the investment decision to purchase the Shares covered by this Agreement (the “Investing Portfolio Manager”) and the portfolio managers or desks who have direct knowledge of the
investment decisions made by the Investing Portfolio Manager. Each Investor covenants that until such time (i) as all material terms of the sale of the Shares to the Investors pursuant to this Agreement are publicly disclosed by the Company,
such Investor and its Affiliates will maintain the confidentiality of the existence and terms of this Agreement and (ii) as all material information set forth in the Disclosure Schedule, if any, are publicly disclosed by the Company, such
Investor and its Affiliates will maintain the confidentiality of all information included on the Disclosure Schedule, other than, in each case, to such Person’s outside attorney, accountant, auditor, investment advisor, or other Representatives
only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law. 

8. Survival and Indemnification. 

8.1. Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing of the
transactions contemplated by this Agreement for the applicable statute of limitations. 
 8.2. Indemnification. The Company agrees to
indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees, members, managers, employees, investment advisers and agents, from and against any and all losses, claims, damages, liabilities and
expenses (including without limitation reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in
connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to which such Person may become subject as a result of any
breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to
the extent such amounts have been finally judicially determined not to have resulted from such Person’s fraud or willful misconduct. 

8.3. Conduct of Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt
written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party;
provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person
unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in
the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying
party in writing that such person elects to 

  
 21 

 
employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and
provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall
materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of
more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to
entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation. No
indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement. 

9. Miscellaneous. 
 9.1.
Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the Company or each of the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its
duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Shares in a transaction complying with applicable securities laws without the prior written consent of the Company or the other Investors, provided
such assignee agrees in writing to be bound by the provisions hereof that apply to Investors. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Without
limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of another
Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person
and the term “Shares” shall be deemed to refer to the securities received by the Investors in connection with such transaction. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

9.2. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other
transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

9.3. Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 

  
 22 

 9.4. Notices. Unless otherwise provided, any notice required or permitted under this
Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given by e-mail, then such notice shall be deemed given upon receipt of confirmation of receipt of an e-mail transmission, (iii) if given by mail, then such notice shall be deemed
given upon the earlier of (A) receipt of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier,
then such notice shall be deemed given one Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days’
advance written notice to the other party: 
 If to the Company: 

Satsuma Pharmaceuticals, Inc. 

400 Oyster Point Boulevard, Suite 221 

South San Francisco, CA 94080 

Attention: Tom O’Neil, Chief Financial Officer 

Email: tom@satsumax.com 
 With a
copy (which shall not constitute notice) to: 
 Latham & Watkins LLP 

Attention: Brian J. Cuneo 
 140
Scott Drive 
 Menlo Park, CA 94025 

Email: Brian.Cuneo@lw.com 
 If
to the Investors: 
 Only to the addresses set forth on the signature pages hereto. 

9.5. Expenses. The parties hereto shall pay their own costs and expenses in connection herewith regardless of whether the transactions
contemplated hereby are consummated; it being understood that each of the Company and each Investor has relied on the advice of its own respective counsel. 

9.6. Amendments and Waivers. No amendment or waiver of any provision of this Agreement will be effective with respect to any party
unless made in writing and signed by a duly authorized representative of such party. 
 9.7. Publicity. Except as set forth below, no
public release or announcement concerning the transactions contemplated hereby shall be issued by any Investors without the prior consent of the Company, except as such release or announcement may be required by law or the applicable rules or
regulations of any securities exchange or securities market, in which case such Investor shall allow the Company reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding the foregoing, each Investor may
identify the 

  
 23 

 
Company and the value of such Investor’s security holdings in the Company in accordance with applicable investment reporting and disclosure regulations or internal policies without prior
notice to or consent from the Company (including, for the avoidance of doubt, filings pursuant to Sections 13 and 16 of the 1934 Act). The Company shall not include the name of any Investor or any Affiliate or investment adviser of such Investor in
any press release or public announcement (which, for the avoidance of doubt, shall not include any SEC Filing to the extent such disclosure is required by SEC rules and regulations) without the prior written consent of such Investor. By 8:30 a.m.
(New York City time) on the Business Day following the date this Agreement is executed, the Company shall issue one or more press releases disclosing all material terms of the transactions contemplated by this Agreement and any other material
nonpublic information that the Company may have provided any Investor at any time prior to the filing of such press releases (the “Press Releases”). From and after the issuance of the Press Releases, no Investor shall be in
possession of any material nonpublic information received from the Company, or any of its officers, directors, employees or agents (including the Placement Agent). No later than 5:30 p.m. (New York City time) on the second Business Day following the
date this Agreement is executed, the Company will file a Current Report on Form 8-K (the “8-K Filing”) attaching or disclosing the details of the press
release(s) described in the foregoing sentence as well as copies of the Transaction Documents. In addition, the Company will make such other filings and notices in the manner and time required by the SEC or Nasdaq. The Company shall not, and shall
cause each of its officers, directors, employees and agents not to, provide any Investor with any material nonpublic information regarding the Company from and after the filing of the Press Releases without the express prior written consent of such
Investor. 
 9.8. Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to
such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by
applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any provision
of law which renders any provision hereof prohibited or unenforceable in any respect. 
 9.9. Benefit of Agreement. The Placement
Agent is an intended third-party beneficiary of the representations and warranties of the Company and of each Investor set forth in Section 4 and Section 5, respectively, of this Agreement. 

9.10. Entire Agreement. This Agreement, including the signature pages, Exhibits, the other Transaction Documents and the confidentiality
agreement between the Company and each Investor constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the
parties with respect to the subject matter hereof and thereof. 
 9.11. Further Assurances. The parties shall execute and deliver all
such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. 

  
 24 

 9.12. Governing Law. This Agreement shall be governed by, and construed in accordance
with, the laws of the State of New York. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this
Agreement. 
 9.13. Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under any
Transaction Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under any Transaction Document. The decision of
each Investor to purchase Shares pursuant to the Transaction Documents has been made by such Investor independently of any other Investor. Nothing contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto,
shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or
the transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor will be acting as agent of
such Investor in connection with monitoring its investment in the Shares or enforcing its rights under the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the
Investors has been provided with the same Transaction Documents for the purpose of closing a transaction with multiple Investors and not because it was required or requested to do so by any Investor. It is expressly understood and agreed that each
provision contained in this Agreement is between the Company and an Investor, solely, and not between the Company and the Investors collectively and not between and among the Investors. 

9.14. Exculpation of the Placement Agent. Each party hereto agrees for the express benefit of the Placements Agent and its affiliates
and representatives that: 
 (i) none of the Placement Agent, its affiliates or any of its representatives (1) has any duties or
obligations other than those specifically set forth herein or in the engagement letter, dated as of February 24, 2021 (the “Engagement Letter”), between the Company and the Placement Agent; (2) shall be liable for any
improper payment made in accordance with the information provided by the Company; (3) makes any representation or warranty, or has any responsibilities as to the validity, accuracy, value or genuineness of any information, certificates or
documentation delivered by or on behalf of the Company pursuant to this Agreement or the Transaction Documents or in connection with any of the transactions contemplated hereby and thereby; or (4) shall be liable (x) for any action taken,
suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or powers conferred upon it by this Agreement or any Transaction Document or (y) for anything which any of them may do
or refrain from doing in connection with this Agreement or any Transaction Document, except in each case for such party’s own gross negligence, willful misconduct or bad faith. 

  
 25 

 (ii) The Placement Agent, its affiliates and its representatives shall be entitled to
(1) rely on, and shall be protected in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to any of them by or on behalf of the Company, and (2) be indemnified by the Company for acting as
the Placement Agent hereunder pursuant to the indemnification provisions set forth in the Engagement Letter. 
 [remainder of page
intentionally left blank] 

  
 26 

 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. 
  

							
	COMPANY:	 		 	SATSUMA PHARMACEUTICALS, INC.
				
		 		 	By:	 	 /s/ John Kollins

		 		 		 	Name: John Kollins
		 		 		 	Title: President and Chief Executive Officer

							
	INVESTOR: Lumira Ventures III, L.P.	 		 	
				
		 		 	By:	 	 /s/ Vasco Larcina

		 		 		 	 Name: Vasco Larcina
 Title: CFO

				
		 		 	By:	 	 /s/ Benjamin Rovinski

		 		 		 	 Name: Benjamin Rovinski
 Title: Sr.
VP

							
	INVESTOR: Lumira Ventures III (International), L.P.	 	
				
		 		 	By:	 	 /s/ Vasco Larcina

		 		 		 	 Name: Vasco Larcina
 Title: CFO

				
		 		 	By:	 	 /s/ Benjamin Rovinski

		 		 		 	 Name: Benjamin Rovinski
 Title: Sr.
VP

  
 29 

							
	INVESTOR: Point72 Associates, LLC
				
		 		 	By:	 	 /s/ Vincent Tortorella

		 		 		 	 Name: Vincent Tortorella
 Title: Authorized
Person

  
 30 

							
	INVESTOR: Shin Nippon Biomedical Laboratories, Ltd.	 	
				
		 		 	By:	 	 /s/ Ryoichi Nagata, MD, PhD

		 		 		 	 Name: Ryoichi Nagata, MD, PhD
 Title:
President & CEO

  
 31 

							
	INVESTOR: Vivo Opportunity Fund, L.P.	 	
				
		 		 	By:	 	 /s/ Gaurav Aggarwal

		 		 		 	 Name: Gaurav Aggarwal
 Title: Managing Member of
Vivo
 Opportunity, LLC, General Partner

  
 32 

							
	INVESTOR: BEMAP Master Fund Ltd	 	
				
		 		 	By:	 	 /s/ Jeff Muller

		 		 		 	 Name: Jeff Muller
 Title: CCO

  
 33 

							
	INVESTOR: DS Liquid Div RVA Mon LLC	 	
				
		 		 	By:	 	 /s/ Jeff Muller

		 		 		 	 Name: Jeff Muller
 Title: CCO

  
 34 

							
	INVESTOR: Bespoke Alpha MAC MIM LP	 	
				
		 		 	By:	 	 /s/ Jeff Muller

		 		 		 	 Name: Jeff Muller
 Title: CCO

  
 35 

							
	INVESTOR: SFL SPV I LLC	 	
				
		 		 	By:	 	 /s/ Jeff Muller

		 		 		 	 Name: Jeff Muller
 Title: CCO

  
 36 

							
	INVESTOR: Monashee Pure Alpha SPV I LP	 	
				
		 		 	By:	 	 /s/ Jeff Muller

		 		 		 	 Name: Jeff Muller
 Title: CCO

  
 37 

							
	INVESTOR: Monashee Solitario Fund LP	 	
				
		 		 	By:	 	 /s/ Jeff Muller

		 		 		 	 Name: Jeff Muller
 Title: CCO

  
 38 

							
	INVESTOR: Ikarian Capital, LLC	 	
				
		 		 	By:	 	 /s/ Chart Westcott

		 		 		 	 Name: Chart Westcott
 Title: COO of Ikarian
Capital, LLC, Investment Adviser

  
 39 

							
	INVESTOR: Commodore Capital Master LP	 	
				
		 		 	By:	 	 /s/ R. Egen Atkinson, MD

		 		 		 	 Name: R. Egen Atkinson, MD
 Title: Authorized
Signatory

  
 40 

							
	INVESTOR: Samlyn Onshore Fund, LP	 	
				
		 		 	By:	 	 /s/ Michael Barry

		 		 		 	 Name: Michael Barry
 Title: Authorized
Signatory

  
 41 

							
	INVESTOR: Samlyn Offshore Master Fund, Ltd.	 	
				
		 		 	By:	 	 /s/ Michael Barry

		 		 		 	 Name: Michael Barry
 Title: Authorized
Signatory

  
 42 

							
	INVESTOR: Samlyn Net Neutral Master Fund, Ltd.	 	
				
		 		 	By:	 	 /s/ Michael Barry

		 		 		 	 Name: Michael Barry
 Title: Authorized
Signatory

  
 43 

							
	INVESTOR: Samlyn Long Alpha Master Fund, Ltd.	 	
				
		 		 	By:	 	 /s/ Michael Barry

		 		 		 	 Name: Michael Barry
 Title: Authorized
Signatory

  
 44 

							
	INVESTOR: Growth Equity Opportunities 17, L.P.	 	
				
		 		 	By:	 	 /s/ Louis S. Citron

		 		 		 	 Name: Louis S. Citron
 Title: Chief Legal
Officer

  
 45 

							
	INVESTOR:	 	 RA CAPITAL HEALTHCARE FUND, L.P.

By: RA Capital Healthcare Fund GP, LLC
 Its: General
Partner

				
		 		 	By:	 	 /s/ Rajeev Shah

		 		 		 	 Name: Rajeev Shah
 Title: Manager

  
 46 

							
	INVESTOR: North Sound Trading, LP	 	
				
		 		 	By:	 	 /s/ Brian Miller

		 		 		 	 Name: Brian Miller
 Title: President of the
General Partner

  
 47 

							
	INVESTOR: Maven Investment Partners US Limited-NY Branch	 	
				
		 		 	By:	 	 /s/ Jose R. Castillo

		 		 		 	 Name: Jose R. Castillo
 Title:
Director

  
 48 

							
	INVESTOR: Ghost Tree Capital Group, LP	 	
				
		 		 	By:	 	 /s/ Matthew Diaz

		 		 		 	 Name: Matthew Diaz
 Title: COO/CFO

  
 49 

							
	INVESTOR:	 	 Logos GLOBAL MASTER FUND LP
 By:
Logos GP LLC
 Its General Partner

				
		 		 	By:	 	 /s/ Arsani William

		 		 		 	 Name: Arsani William
 Title: Managing
Partner

  
 50 

							
	INVESTOR:	 	 ASPIRE CAPITAL FUND, LLC
 By: Aspire
Capital Partners, LLC
 By: SGM Holdings Corp.

				
		 		 	By:	 	 /s/ Steven G. Martin

		 		 		 	 Name: Steven G. Martin
 Title:
President

  
 51 

							
	INVESTOR:	 	 Citadel Multi-Strategy Equities Master Fund Ltd.

By: Citadel Advisors LLC, its portfolio manager

				
		 		 	By:	 	 /s/ Shellane Mulcahy

		 		 		 	 Name: Shellane Mulcahy
 Title: Authorized
Signatory

  
 52 

 EXHIBIT A 

Schedule of Investors 
  

									
	 Investor Name
	  	Number of Shares to be
Purchased	 	 	Aggregate Purchase Price of Shares	 
	 Lumira Ventures III, L.P.
	  	 	340,773	 	 	$	1,935,590.64	 
	 Lumira Ventures III (International), L.P.
	  	 	11,339	 	 	$	64,405.52	 
	 Point72 Associates, LLC
	  	 	528,169	 	 	$	2,999,999.92	 
	 Shin Nippon Biomedical Laboratories, LTD
	  	 	1,232,394	 	 	$	6,999,997.92	 
	 Vivo Opportunity Fund, L.P.
	  	 	1,232,394	 	 	$	6,999,997.92	 
	 BEMAP Master Fund Ltd
	  	 	45,005	 	 	$	255,628.40	 
	 DS Liquid Div RVA MON LLC
	  	 	53,748	 	 	$	305,288.64	 
	 Bespoke Alpha MAC MIM LP
	  	 	6,530	 	 	$	37,090.40	 
	 SFL SPV I LLC
	  	 	7,803	 	 	$	44,321.04	 
	 Monashee Pure Alpha SPV I LP
	  	 	27,992	 	 	$	158,994.56	 
	 Monashee Solitario Fund LP
	  	 	34,979	 	 	$	198,680.72	 
	 Ikarian Healthcare Master Fund, LP
	  	 	[176,057	] 	 	[$	1,000,003.76	] 
	 Boothbay Absolute Return Strategies, LP
	  	 	[    	] 	 	 	[    	] 
	 Boothbay Diversified Alpha Master Fund, LP
	  	 	[    	] 	 	 	[    	] 
	 Commodore Capital Master LP
	  	 	1,575,000	 	 	$	8,946,000.00	 
	 Samlyn Onshore Fund, LP
	  	 	215,595	 	 	$	1,224,579.60	 
	 Samlyn Offshore Master Fund, Ltd
	  	 	540,879	 	 	$	3,072,192.72	 
	 Samlyn Net Neutral Master Fund, Ltd
	  	 	434,262	 	 	$	2,466,608.16	 
	 Samlyn Long Alpha Master Fund, Ltd
	  	 	41,658	 	 	$	236,617.44	 
	 Growth Equity Opportunities 17, L.P.
	  	 	2,992,958	 	 	$	17,000,001.44	 
	 RA Capital Healthcare Fund, L.P.
	  	 	1,232,394	 	 	$	6,999,997.92	 
	 North Sound Trading, LP
	  	 	361,620	 	 	$	2,054,001.60	 

  
 53 

									
	 Investor Name
	  	Number of Shares to be
Purchased	 	  	Aggregate Purchase Price of Shares	 
	 Maven Investment Partners US Limited-NY Branch
	  	 	88,029	 	  	$	500,004.72	 
	 Ghost Tree Master Fund, LP
	  	 	123,381	 	  	$	700,804.08	 
	 NR 1 SP, a Segregated Portfolio of North Rock SPC
	  	 	143,110	 	  	$	812,864.80	 
	 NR 2, a Segregated Portfolio of North Rock SPC
	  	 	143,361	 	  	$	814,290.48	 
	 Schonfeld EXT Master Fund, LP
	  	 	203,344	 	  	$	1,154,993.92	 
	 Squarepoint Diversified Partners Fund Limited
	  	 	91,029	 	  	$	517,044.72	 
	 Aspire Capital Fund, LLC
	  	 	792,254	 	  	$	4,500,002.72	 
	 Citadel Multi-Strategy Equities Master Fund Ltd.
	  	 	880,281	 	  	$	4,999,996.08	 
	 Logos Global Master Fund LP
	  	 	528,169	 	  	$	2,999,999.92	 
	 TOTAL
	  	 	14,084,507	 	  	$	79,999,999.76	 

  
 54 

 EXHIBIT B 

Form of Registration Rights Agreement 

[Attached as Exhibit 10.2 to Current Report on Form 8-k] 

  
 55 

 DISCLOSURE SCHEDULE 

  
 56

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]